Phaseline

Companies › Genmab

Genmab: clinical trials, targets and expected readouts

9 active drug programs in 68 registered trials: 31 Phase 2, 21 Phase 1, 16 Phase 3; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Epcoritamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Diffuse Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma …Mar 2027
Acasunlimab
Bispecific antibody that engages PD-L1 and 4-1BB
CD274, TNFRSF9Phase 3PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLCJul 2027
Rina-S
Topoisomerase 1 inhibitor conjugate (SN-38 payload on anti-TROP-2 antibody)
TOPO1Phase 3Platinum-resistant Ovarian Cancer; Ovarian Cancer; Endometrial Cancer; Platinum-Sensitive Ovarian Cancer …Sep 2027
Petosemtamab (MCLA-158)
bispecific antibody targeting EGFR and LGR5
EGFR, CEACAM5, LGR5Phase 3Head and Neck Squamous Cell Carcinoma; Colorectal Cancer; Left-sided Colorectal Cancer; Advanced/Metastatic Solid TumorsJan 2028
GEN1042
Bispecific antibody targeting CD40 and 4-1BB (TNFRSF18); DuoBody format
CD40, TNFRSF18Phase 1Malignant Solid TumorJan 2027
GEN1106–Phase 1Solid TumorsApr 2029
GEN1119–Phase 1Solid TumoursJun 2029
GEN3018
Antibody
–Phase 1R/R AMLOct 2029
GEN1079–Phase 1Advanced Solid TumorsJan 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06287398EpcoritamabPhase 2DLBCL - Diffuse Large B Cell LymphomaOncologyNov 2026
NCT06672705EpcoritamabPhase 1Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative DisorderOncologyDec 2026
NCT04083599GEN1042Phase 1Malignant Solid TumorOncologyJan 2027
NCT06723457EpcoritamabPhase 2Recurrent B-Cell Non-Hodgkin LymphomaOncologyFeb 2027
NCT05451810EpcoritamabPhase 2Diffuse Large B-Cell LymphomaOncologyMar 2027
NCT06510491EpcoritamabPhase 2Waldenstrom MacroglobulinemiaOncologyApr 2027
NCT05578976EpcoritamabPhase 3Diffuse Large B-Cell LymphomaOncologyJun 2027
NCT07108998EpcoritamabPhase 2CLL/SLLOncologyJul 2027
NCT06676033EpcoritamabPhase 1Leukemia, Chronic LymphocyticOncologyJul 2027
NCT06635824AcasunlimabPhase 3PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLCOncologyJul 2027
NCT06112847EpcoritamabPhase 2Follicular LymphomaOncologyAug 2027
NCT06057038GEN1042Phase 1Malignant Solid TumorOncologyAug 2027
NCT06536049EpcoritamabPhase 1Recurrent Diffuse Large B-Cell LymphomaOncologyAug 2027
NCT07604766Rina-SPhase 3Platinum-resistant Ovarian CancerOncologySep 2027
NCT04542824EpcoritamabPhase 1Diffuse Large B Cell LymphomaOncologySep 2027
NCT07451652EpcoritamabPhase 2Relapsed/Refractory Diffuse Large B Cell LymphomaOncologySep 2027
NCT04663347EpcoritamabPhase 1Diffuse Large B-Cell LymphomaOncologySep 2027
NCT06619236Rina-SPhase 3Platinum-resistant Ovarian CancerOncologyOct 2027
NCT05201248EpcoritamabPhase 1B-Cell Non-Hodgkin LymphomaOncologyOct 2027
NCT06458439EpcoritamabPhase 2Lymphoma, Non-HodgkinOncologyOct 2027
NCT07288177Rina-SPhase 2Non-small Cell Lung Cancer (NSCLC)OncologyNov 2027
NCT05852717EpcoritamabPhase 2Large Cell Lymphoma, DiffuseOncologyNov 2027
NCT04623541EpcoritamabPhase 1Relapsed/Refractory Chronic Lymphocytic LeukemiaOncologyDec 2027
NCT06931652EpcoritamabPhase 2Primary CNS Lymphoma (PCNSL)OncologyJan 2028
NCT06525220Petosemtamab (MCLA-158)Phase 3Head and Neck Squamous Cell CarcinomaOncologyJan 2028
NCT05783609EpcoritamabPhase 2Follicular LymphomaOncologyFeb 2028
NCT06496178Petosemtamab (MCLA-158)Phase 3Head and Neck Squamous Cell CarcinomaOncologyFeb 2028
NCT06508658EpcoritamabPhase 3Diffuse Large B-Cell LymphomaOncologyMar 2028
NCT04628494EpcoritamabPhase 3Diffuse Large B-cell LymphomaOncologyApr 2028
NCT06510361EpcoritamabPhase 2LymphomaOncologyMay 2028
NCT06414148EpcoritamabPhase 2Relapsed/Refractory Large B-cell LymphomaOncologyMay 2028
NCT03526835Petosemtamab (MCLA-158)Phase 1Advanced/Metastatic Solid TumorsOncologyMay 2028
NCT07226752EpcoritamabPhase 3Diffuse Large B-Cell LymphomaOncologyJun 2028
NCT06905509EpcoritamabPhase 2Recurrent Diffuse Large B-Cell LymphomaOncologyJul 2028
NCT06045247EpcoritamabPhase 2Large B-cell LymphomaOncologyJul 2028
NCT07082868EpcoritamabPhase 1Primary Central Nervous System Lymphoma (PCNSL)OncologyAug 2028
NCT06447376EpcoritamabPhase 1Non-Hodgkin LymphomaOncologySep 2028
NCT07539311Rina-SPhase 2Gastrointestinal CancersOncologySep 2028
NCT06811272EpcoritamabPhase 2Relapsed Large B-cell LymphomaOncologyOct 2028
NCT07883135EpcoritamabPhase 2Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)OncologyOct 2028
NCT07225270Rina-SPhase 3Ovarian CancerOncologyOct 2028
NCT06796998EpcoritamabPhase 2Marginal Zone LymphomaOncologyOct 2028
NCT05206357EpcoritamabPhase 1Non-hodgkin LymphomaOncologyNov 2028
NCT05579366Rina-SPhase 1High Grade Epithelial Ovarian CancerOncologyDec 2028
NCT03625037EpcoritamabPhase 1DLBCLOncologyJan 2029
NCT05791409EpcoritamabPhase 1CLL/SLLOncologyMar 2029
NCT07775287Petosemtamab (MCLA-158)Phase 3Colorectal CancerOncologyMar 2029
NCT07416123GEN1106Phase 1Solid TumorsOncologyApr 2029
NCT05848765EpcoritamabPhase 2Relapsed Follicular LymphomaOncologyMay 2029
NCT07218510EpcoritamabPhase 2Chronic Lymphocytic LeukemiaOncologyJun 2029
NCT07695831GEN1119Phase 1Solid TumoursOncologyJun 2029
NCT07702032Petosemtamab (MCLA-158)Phase 3Left-sided Colorectal CancerOncologyJul 2029
NCT07166094Rina-SPhase 3Endometrial CancerOncologyAug 2029
NCT07365306EpcoritamabPhase 2Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedOncologyOct 2029
NCT07384715GEN3018Phase 1R/R AMLOncologyOct 2029
NCT07564141Rina-SPhase 3Platinum-Sensitive Ovarian CancerOncologyDec 2029
NCT05409066EpcoritamabPhase 3Follicular Lymphoma (FL)OncologyDec 2029
NCT06238648EpcoritamabPhase 2Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedOncologyDec 2029
NCT06563596EpcoritamabPhase 2Follicular LymphomaOncologyMar 2030
NCT07197307EpcoritamabPhase 2Aggressive Diffuse Large B-cell LymphomaOncologyApr 2030

The 60 nearest readouts of 68 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of $1.7bn on 2025-12-31; operating cash flow positive

Targets

TOPO1 (1) MS4A1 (1) CD3E (1) CD3G (1) CD3D (1) CD40 (1) TNFRSF18 (1) EGFR (1) CEACAM5 (1) LGR5 (1) CD274 (1) TNFRSF9 (1)

Companies with the same targets

Roche Johnson & Johnson (Janssen) Amgen Regeneron Pharmaceuticals AbbVie AstraZeneca Tiziana Life Sciences Pfizer Biocad Novartis

Companies built like this

Immunocore Exelixis Shanghai JMT-Bio LaNova Medicines Prestige Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.